Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from WedbushMarket Beat·Jul 21 at 09:18 AMSRRK-3.66%
Scholar Rock announces press release on apitegromab CHMP opinion timing for SMA MAAPUBT·Jul 20 at 07:05 AMSRRK-3.66%
Leerink Partners Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)Tip Ranks·Jul 17 at 07:55 AMSRRK-3.66%
Scholar Rock to report Q2 2026 financial results, host conference callPUBT·Jul 16 at 07:00 AMSRRK-3.66%
Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTHrttnews·Jul 13 at 06:18 AMSRRK-3.66%CUE-2.93%
Scholar Rock Holding Corporation Stock 12‑Month Price Target Raised to $60.07, Implies 6% UpsideTradingView·Jul 7 at 11:20 PMSRRK-3.66%
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from AnalystsMarket Beat·Jul 1 at 01:15 AMSRRK-3.66%
Scholar Rock (NASDAQ:SRRK) Reaches New 52-Week High - What's Next?Market Beat·Jun 24 at 11:40 AMSRRK-3.66%
Scholar Rock presents Phase 3 SAPPHIRE post hoc analyses for apitegromab in nonambulatory SMA patientsPUBT·Jun 22 at 07:01 AMSRRK-3.66%
Scholar Rock Holding (SRRK) Stock Could Be 14.1% Undervalued On Its SMA NarrativeSimplywall·Jun 21 at 06:08 PMSRRK-3.66%
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SRRK Stock NewsStockTitan·Jun 12 at 07:15 AMSRRK-3.66%
